HUM-MOLGEN events: BLOOD PRODUCT SAFETY

HUM-MOLGEN -> Events -> Meetings and Conferences

December 05, 2000

Cambridge Healthtech Institute, McLean, Virginia
February 5-7, 2001

Human blood and plasma contain many proteins, the extraction and purification of which are of great medical and economic importance. Transmission of infectious diseases via blood transfusion, immune response to transfusion, and the use of processed blood plasma and components have placed a high priority on the development of new strategies for safeguarding the health of the millions of patients who receive blood-derived products every year. The screening of blood for the detection of infectious agents is continuing to advance but is complicated by new and emerging pathogens. In addition, cost-effectiveness and the threat of emerging and/or crossover infective agents must also be considered. Recent advances and new strategies for the inactivation and removal of infectious agents in whole blood, cord blood, component concentrates, and plasma, as well as methods to prevent and monitor blood transfusion errors, are the focus of CHI's Seventh Annual Blood Product Safety conference.

Organized by:

Cambridge Healthtech Institute

Invited Speakers:

Dr. Kathleen Beach, V. I. Technologies, Inc.
Mr. Noah L. Bentley, Wyndgate Technologies, a Division of Global Med Technologies, Inc.
Dr. Peter Bergvall, Amersham Pharmacia Biotech (Sweden)
Mr. Noel R. Brown, Immucor, Inc.
Dr. Paul W. Brown, National Institute of Neurological Disorders and Stroke, N.I.H.
Dr. Wilson Burgess, Clearant Inc.
Dr. Larisa Cervenakova, American Red Cross
Dr. John Chapman, V.I Technologies, Inc.
Dr. William H. Cover, PurePulse Technologies, Inc
Ms. Sylvia Crush-Stanton, Boston Biomedica, Inc.
Dr. Rodeina Davis, Mediware Information Systems, Inc.
Dr. William Drohan, Clearant Inc.
Dr. Chyang Fang, Chiron Corporation
Dr. Timothy C. Fisher, University of Southern California
Dr. Pierluigi Gambetti, Case Western Reserve University
Ms. Nancy Heddle, McMaster University Medical Center (Canada)
Dr. John Hess, United States Army Medical Corps.
Dr. Harry Hiemstra, CLB, Amsterdam (The Netherlands)
Dr. Bernard Horowitz, Horowitz Consultants, LLC
Dr. Herwig Igel, Baxter Hyland Immuno (Austria)
Dr. Harold Kaplan, Columbia-Presbyterian Hospital
Dr. W. Richard Light, Biopure Corporation
Dr. Thomas Lynch, Clearant Inc.
Dr. Kathleen MacPhee, Pathobiotek Diagnostics, Inc
Dr. Martin MacPhee, Clearant Inc.
Dr. Mark Manak, Boston Biomedica, Inc.
Dr. Graham D. Sher, Canadian Blood Services (Canada)
Dr. Lorraine Peddada, Alpha Therapeutic Corporation
Dr. Janet Rider, The Bristol Institute for Transfusion Services (UK)
Dr. Sherril J. Slichter, Puget Sound Blood Center
Dr. Tsugikazu Tomono, Japanese Red Cross (Japan)
Dr. Richard H. Tullis, Aethlon Medical, Inc.
Dr. Hannalore Willkommen, Paul-Ehrlich Institut (Germany)
Dr. Gerold Zerlauth, Baxter Hyland Immuno (Austria)

Deadline for Abstracts:

January 5, 2001

Registration:

Available on-line

E-mail:

jlaakso@healthtech.com

Posted by:

Jennifer Laakso

Host:

wks217.healthtech.com